






SUPPORTING INFORMATION


Supplemental Figures




Supplemental Figure S1. Φ/Ψ angle RMSD versus normalized C α RMSD for alpha helical peptides, Related to Figure 2. A. Φ (red) and Ψ (blue) angle RMSD plotted against the C α RMSD per residue for each alpha helical membrane peptide (AH MP) in our benchmark set. **B.** Φ (red) and Ψ (blue) angle RMSD plotted against the C α RMSD per residue for each alpha helical soluble (AH SL) peptide in our benchmark set. Φ/Ψ RMSD and C α RMSD was calculated pairwise for all 5 AF2 models compared to each model in the NMR ensemble. The minimum RMSD among pairwise comparisons was plotted.

A**B**


Supplemental Figure S2. Φ/Ψ angle RMSD versus normalized C α RMSD for mixed secondary structure peptides, Related to Figure 3. **A.** Φ (red) and Ψ (blue) angle RMSD plotted against the C α RMSD per residue for each mixed secondary structure membrane peptide (MIX MP) in our benchmark set. **B.** Φ (red) and Ψ (blue) angle RMSD plotted against the C α RMSD per residue for each mixed secondary structure soluble (MIX SL) peptide in our benchmark set. Φ/Ψ RMSD and C α RMSD was calculated pairwise for all 5 AF2 models compared to each model in the NMR ensemble. The minimum RMSD among pairwise comparisons was plotted.




Supplemental Figure S3. Φ/Ψ angle RMSD versus normalized C α RMSD for β -hairpin and disulfide rich peptides, Related to Figure 4. **A. Φ (red) and Ψ (blue) angle RMSD plotted against the C α RMSD per residue for each β -hairpin peptide (BHPIN) in our benchmark set. **B.** Φ (red) and Ψ (blue) angle RMSD plotted against the C α RMSD per residue for each disulfide rich peptide (DSRP) in our benchmark set. Φ/Ψ RMSD and C α RMSD was calculated pairwise for all 5 AF2 models compared to each model in the NMR ensemble. The minimum RMSD among pairwise comparisons was plotted.**



Supplemental Figure S4. X-ray models versus AlphaFold2 compared to NMR models versus AlphaFold2, Related to Star Methods. There was not a statistically significant difference between AF2's ability to predict NMR vs. Xray crystal structures. Surprisingly, NMR/X-ray RMSD comparisons failed to demonstrate lower RMSD than AF2 vs. either method, demonstrating the draw backs of both experimental and computational techniques.



Supplemental Figure S5. Number of lowest RMSD model pairs by pLDDT ranking, Related to Star Methods. AF2 ranks structures by backbone pLDDT. We enumerated the number of rank 1, rank 2 etc. by pLDDT AF2 models for each lowest RMSD NMR model/AF2 model pairwise comparison in our benchmark set. This bar graph showed rank 1-3 models are more likely to predict NMR models than rank 4 and 5 AF2 models.



Supplementary Figure S6. AlphaFold2 predicted short peptides with higher accuracy than long peptides, Related to Figure 5. A. Scatter plot of C α RMSD versus peptide length demonstrates a positive trend, which increasing C α RMSD for longer peptides. Point color coded by peptide type with DSRPs in red, BHPINs in orange, AH MP in blue, AH SL in green, MIX MP in yellow, and MIX SL in purple. Note, DSRPs showed the least correlation and make up most long length peptides. These peptides also have more contacts and thus AF2 was better at folding them because MSAs provided structural information, unlike for the more unstructured peptide class considered in this study. **B.** The same scatter plot with the y axis adjusted from 1.0 to 3.0 Å for clear viewing of low C α RMSD range.

Supplemental Tables

Supplemental Table 2, in relation to Figure 4: List of all the DSRP disulfide connectivity patterns as identified in experimental structures versus AF2-predicted structures, along with information on whether the particular peptide was identified as an RMSD outlier.

NMR disulfide bond pattern		AF2 disulfide bond pattern		RMSD outliers?
1EWS				
3	29	3	28	n
5	12	5	19	
9	28	9	29	
1G26				
4	16	4	26	n
10	26	10	16	
1IM1				
2	18	3	12	n
3	12	-	-	
1KOP				
2	28	7	28	n
7	25	-	-	
1M4E				
2	18	2	18	n
5	17	5	8	
6	14	6	14	
8	9	9	17	
1M4F				
7	23	7	23	y
10	22	10	12	
11	19	11	19	
13	14	13	22	
1N5G				
4	30	4	27	y
9	27	9	30	
1S6W				
2	19	2	19	n
5	18	5	8	
6	15	6	15	
8	9	9	18	

1TYK				
2	17	2	16	n
9	23	9	9	
16	30	17	30	
2B5B				
4	30	4	29	y
8	29	8	24	
12	24	12	30	
2BBG				
5	35	5	18	y
11	26	11	28	
18	28	19	39	
19	39	-	-	
2DDL				
3	23	3	23	n
8	28	8	28	
12	30	12	30	
18	33	-	-	
2L1J				
1	16	1	16	n
8	15	8	22	
24	31	15	33	
		24	31	
2MIX				
4	20	4	21	y
5	21	7	16	
7	16	-	-	
2MM5				
1	16	1	16	n
8	15	8	21	
		15	29	
2MSF				
4	12	4	21	y
7	28	7	26	
11	21	11	28	
16	26	-	-	
3BBG				
5	35	5	11	y
11	26	18	26	

18	28	19	39	
19	39			
6NUG				
1	13	1	13	n
7	23	7	23	
14	24	-	-	
6NW8				
2	23	12	23	y
5	18			
12	25			
7ELY				
2	25			y
12	26	12	28	
14	20			
7L7A				
2	9	-	-	y
3	11	-	-	

Supplemental Table 3, in relation to Star Methods: The PDB IDs, range of the structured regions, length and sequence information, and the description of the peptides used for the comparison of NMR and X-ray structures that have identical ordered regions.

NMR PDB ID	Xray PDB ID	Type	Structured Region for RMSD calculation	NMR FASTA Sequence	Xray FASTA sequence	Length	Description
2U VS	3O DV	DS RP	1-38	GVEINVKCSGSPQCLKPCKDA GMRFGKCMNRKCHCTPK	GVEINVKCSGSPQCLKPCKDA GMRFGKCMNRKCHCTPK	38	High Resolution Solid-state NMR structure of Kaliotoxin
1E 4Q	1F D3	DS RP	28-64	PVTCLKSGAICHVPVFCPRRYK QIGTCGLPGTKCCKKP	GIGDPVTCLKSGAICHVPVFCP RRYKQIGTCGLPGTKCCKKP	37	Solution structure of the human defensin hBD-2
1E 4S	1IJ U	DS RP	33-68	DHYNCVSSGGQCLYSACPIFT KIQTGTCYRGKAKCCK	DHYNCVSSGGQCLYSACPIFT KIQTGTCYRGKAKCCK	36	Solution structure of the human defensin hBD-1
1E RC	6E 6O	DS RP	1-40	DACEQAAIQCVESACESLCTE GEDRTGTCYMYIYNSCPPYV	DACEQAAIQCVESACESLCTE GEDRTGTCYMYIYNSCPPYV	40	THE NMR SOLUTION STRUCTURE OF THE PHEROMONE ER-1 FROM THE CILIATED PROTOZOAN EUPLOTES RAIKOVI
1Q 2K	3E 8Y	DS RP	1-31	AACYSSDCRVKCVAMGFSSG KCINSKCKCYK	AACYSSDCRVKCVAMGFSSG KCINSKCKCYK	31	Solution structure of BmBKTx1 a new potassium channel blocker from the Chinese Scorpion Buthus martensi Karsch

1R O O	4L FQ	DS RP	3-35	RSCIDTIPKSRCTAFQCKHSM KYRLSFCRKTCGTC	RSCIDTIPKSRCTAFQCKHSM KYRLSFCRKTCGTC	35	NMR SOLUTION STRUCTURE OF SHK TOXIN, NMR, 20 STRUCTURES
1T SK	6A TL	DS RP	1-35	VVIGQRCYRSPDCYSACKLV GKATGKCTNGRCDC	GSVVIGQRCYRSPDCYSACKK LVGKATGKCTNGRCDC	35	SCORPION TOXIN (TS KAPPA) FROM TITYUS SERRULATUS ACTIVE ON SMALL CONDUCTANCE POTASSIUM CHANNEL, NMR, 30 STRUCTURES
1V 6R	6D K5	DS RP	1-21	CSCSSLMDKECVYFCHLDIIW	CSCSSLMDKECVYFCHLDIIW	21	Solution Structure of Endothelin-1 with its C- terminal Folding
1Z FU	3E 7R	DS RP	4-40	GFGCNGPWDEDDMQCHNH CKSIKGYKGGYCAKGGFVCKC Y	GFGCNGPWDEDDMQCHNH CKSIKGYKGGYCAKGGFVCKC Y	40	Plectasin:A peptide antibiotic with therapeutic potential from a saprophytic fungus
2K HB	4T M	DS RP	4-28	GLPVCGETCVGGTCNTPGCT CSWPVCTRN	GLPVCGETCVGGTCNTPGCT CSWPVCTRN	29	Solution structure of linear kalata B1 (loop 6)
2K TX	3O DV	DS RP	3-38	GVEINVKCSGSPQCLKPCKDA GMRFGKCMNRKCHCTPK	GVEINVKCSGSPQCLKPCKDA GMRFGKCMNRKCHCTPK	38	COMPLETE KALIOTOXIN FROM ANDROCTONUS MAURETANICUS MAURETANICUS, NMR, 18 STRUCTURES
2L XZ	1Z M P	DS RP	1-32	ATCYCRTGRCATRESLSGVCEI SGRLYLCCR	ATCYCRTGRCATRESLSGVCEI SGRLYLCCR	32	Solution Structure of the Antimicrobial Peptide Human Defensin 5
2 M AU	4B FH	DS RP	1-30	CAQKGEYCSVYLQCCDPYHC TQPVIIGICA	CAQKGEYCSVYLQCCDPYHC TQPVIIGICA	30	Solution structure of alpha-amylase inhibitor wrightide R1

							(wR1) peptide from <i>Wrightia religiosa</i>
2N 9T	5O 0U	DS RP	1-28	YCQKWMWTCDSERKCEG MVCRLWCKKKLW	YCQKWMWTCDSERKCEG MVCRLWCKKKLW	30	NMR solution structure of ProTx-II
2V 1V	1L U0	DS RP	2-29	RVCPRILLECKKSDCLAECVC LEHGYCG	RVCPRILLECKKSDCLAECVC LEHGYCG	29	3D STRUCTURE OF THE M8L MUTANT OF SQUASH TRYPSIN INHIBITOR CMTI-I
5L 1C	6A T W	DS RP	1-36	MCMPCFTTDHQMARKCDD CCGGKGRGKCYGPQCLCR	GSMCMPCFTTDHQMARKC DDCCGGKGRGKCYGPQCLCR	36	Heteronuclear Solution Structure of Chlorotoxin